Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
Retrieved on:
Monday, May 16, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Muscular dystrophy, ANSM, Health care, EST, EMA, FKRP, Master of Science, European Society of Gene and Cell Therapy, Therapy, Research, National Medicinal Drugs Policy, CMC, Lists of diseases, Orphan, Quality, Supply chain, Vaccine, Patient, Degenerative disease, CTA, European Medicines Agency, Cell, MBA, Sanofi Pasteur, CNRS, LGMD, Poster, MHRA, Date, Technology, CTO, Orphan drug, Hope, Gene, Industry, AAV, Life, Weakness, Master of Engineering, CEO, Pharmaceutical industry, Management
ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
Key Points:
- ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
- Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
- A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
- Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.